Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153591 · ClinicalTrials.gov registry record
Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 75
- Enrollment target
NCT04153591: Completed study, sponsored by Methodist Health System.
NCT04153591 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04153591 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal evidence to support the use of DOACs for Left Atrial Appendage (LAA) thrombus and Left Ventricular Thrombus (LVT), and a lack of evidence for the use of DOACs in aortic thrombus, further research is warranted to determine the role of DOACs in the treatment of various mural thrombi in comparison to warfarin.
Primary Outcome
Readmission for recurrent stroke or thromboembolic event within 90 days of initial hospital discharge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-11-05 |
| Est. Completion | 2020-06-22 |
What the finished NCT04153591 record still lists
NCT04153591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04153591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04153591 about?
NCT04153591 is a clinical study titled "Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus". To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal e...
What is the current status of trial NCT04153591?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2019-11-05. Estimated completion is 2020-06-22.
Who is sponsoring clinical trial NCT04153591?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI